Bridge BIO
Seongnam-si, South Korea · Founded 2015
- Headquarters
- Seongnam-si
- Employees
- 11–50
- Founded
- 2015
- Business Model
- B2B
- Website
- bridgebiorx.com
About
Bridge Biotherapeutics Inc. is a publicly-traded clinical-stage biotechnology company headquartered in Seongnam-si, South Korea, with offices in Cambridge, Massachusetts and China. Founded in 2015 by CEO James Jungkue Lee, the company focuses on discovering and developing novel therapeutics for high unmet medical needs, including ulcerative colitis, fibrotic diseases such as idiopathic pulmonary fibrosis, and cancers including non-small cell lung cancer. Its pipeline features BBT-401 (a first-in-class Pellino-1 inhibitor), BBT-877 (an autotaxin inhibitor for IPF), and BBT-176 (a targeted EGFR-mutant NSCLC therapy).
Summary
Bridge BIO is a Biotech company based in Seongnam-si, South Korea, founded in 2015.
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/bridge-bio"><img src="https://indexed.vc/api/badge/company/bridge-bio" alt="Bridge BIO on Indexed.vc" width="260" height="76" /></a>